• Results suggest that FAEs are superior to placebo, but their efficacy in comparison with methotrexate is uncertain due to very low-quality evidence.
• The relative risk of nuisance adverse effects with FAEs is about five times greater than with placebo; however, there is insufficient evidence available to give an accurate figure for dropout rates due to adverse effects.
Psoriasis is a chronic inflammatory skin disease with various subtypes, of which chronic plaque psoriasis is the most common. 1 Fumaric acid esters (FAEs) were first used in the treatment of psoriasis in 1959 after successful self-experimentation by Schweckendiek, a German chemist who proposed that psoriasis was caused by a disturbance in the citric acid cycle in which fumaric acid was lacking. 2 FAEs contain dimethylfumarate (DMF), believed to be the active component, and salts of ethyl hydrogen fumarate. 3 Fumaderm â Initial (Biogen Idec, Cambridge, MA, U.S.A.), containing 30 mg of DMF per tablet, and Fumaderm â , containing 120 mg of DMF per tablet, are commercially available and have been licensed for the treatment of psoriasis in Germany since 1994. 4 They are also used for psoriasis treatment as off-label drugs in many other countries. The aim of this Cochrane review was to provide the best available evidence for the efficacy and safety of FAEs in the treatment of psoriasis. The results are summarized in this report, and the full review is available in the Cochrane Library. 5 
Material and methods
This systematic review was carried out according to a prespecified protocol 6 and incorporated Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. 7 
Search strategies
An electronic search for relevant studies was carried out up to May 2015 using the Cochrane Skin Group Specialised Register, 
Inclusion criteria
We included RCTs that involved participants of either sex, and any age or ethnicity, with a clinical diagnosis of psoriasis of any subtype, where FAEs, as monotherapy or in combination, were compared with placebo or any other active treatment.
Types of outcome measures
The primary outcomes were Psoriasis Area and Severity Index (PASI) score and dropout rates due to adverse effects. Other outcomes of interest were quality-of-life scores measured with a validated scale; the proportion of participants achieving ≥ 50%, ≥ 75% and ≥ 90% improvement in PASI (PASI 50, 75 and 90); the proportion of participants experiencing serious adverse effects and those experiencing nonserious nuisance adverse effects.
Data extraction and synthesis
The titles and abstracts of retrieved studies were screened by two authors independently (A.A. and R.A.). The full texts of potentially eligible studies were examined by the same authors who extracted data from eligible studies using a data extraction form based on the 'checklists of items to consider in data extraction'; 8 a third author (J.R.I.) adjudicated on disagreements.
Review Manager, 9 the software used for Cochrane reviews, was used for statistical analysis with a fixed-effects model. For dichotomous outcomes we pooled risk ratios (RRs) with 95% confidence intervals (CIs), while we combined the mean difference (MD) with 95% CI for continuous outcomes. We made contact with trial authors whenever possible to request relevant unreported data. Statistical heterogeneity was assessed using I 2 statistics; we took a narrative approach if the I 2 value exceeded 75%. 10 The quality of evidence for each outcome was ranked using GRADEpro software, from which we produced our 'summary of findings' tables.
Results

Description of the included studies
In total, 94 records were identified through the initial search: database searching (n = 80), hand searching (n = 6) and trials registers (n = 8) (Fig. 1 ). These included eight ongoing studies and eight duplicate reports, which were excluded, giving a total of 78 records. Of these, 11 potentially eligible studies were identified after screening the titles and abstracts. After reading the full texts, five articles were excluded due to failure to meet our prespecified inclusion criteria [11] [12] [13] [14] and lack of evidence of randomization. 15 As a result, six studies with a total of 544 participants were included in our review; five compared FAE with placebo [16] [17] [18] [19] [20] and one used methotrexate as an active comparator. 21 The included studies were reported between 1990 and 2011. Only two of the six studies were published in full reports, 16, 21 whereas the others were available in a brief communication, 19 a letter 20 and abstracts. 17, 18 We were unable to obtain the full reports of published abstracts by contacting the authors. Despite the limitations of incompletely reported studies, we decided it was important to include them in our review because of the limited number of eligible RCTs. Three of the included studies were carried out in the Netherlands, [19] [20] [21] one of which was designed to measure the effect of FAEs in the treatment of psoriatic arthritis. 20 However, contact with the authors confirmed that all participants had concomitant psoriasis, so we included this study to obtain safety data. All of the included studies involved adults aged > 18 years, except one study that did not report the participants' ages. 17 Participants in the included studies had chronic plaque psoriasis in two studies; 18, 21 various psoriasis subtypes in two studies (chronic plaque, guttate, pustular and erythrodermic) 16, 17 and unreported psoriasis subtype in two studies. 19, 20 PASI score at baseline was reported in only three studies, and was required to be ≥ 10 in one study, 21 ≥ 12 in one study 18 and 16-24 in one study. 17 Outcome reporting was at 12-16 weeks in all of the included studies, but not all of our prespecified outcomes were reported in every study. None of the included studies reported data on economic evaluations.
Risk of bias in the included studies
Three of the included studies had 'high risk' of bias in at least one domain. 16, 17, 21 Insufficient reporting in most of the included studies, due to lack of full reports and old publications, rendered the risk of bias for most domains 'unclear' (Fig. 2) .
Effects of interventions
Due to the lack of opportunities for meta-analyses, we used mainly a narrative approach to present the effects of FAEs in the treatment of psoriasis. The only exception was for the secondary outcome PASI 50 when FAEs were compared with placebo, where data from two studies were combined.
Comparison of fumaric acid esters with placebo
Three of the five studies comparing FAEs with placebo used a mixture of DMF plus monoethylfumarate as an intervention, 16, 19, 20 whereas DMF alone was used in the other two studies. 17, 18 Two of the included studies 17, 18 were reported in abstracts only; contact with the lead author 18 confirmed that the studies were not reported in full manuscripts and only the data contained in the abstracts are available. In view of the limited number of eligible studies, and in agreement with the Cochrane Editorial Unit, we included these abstracts in our review. The quality of evidence for each outcome is presented in Table 1 . Altmeyer et al. 16 reported a reduction of PASI score from a mean of 21Á57 at baseline to 10Á77 after 16 weeks of FAE treatment, whereas in the placebo group it remained the same (P < 0Á001). Langner et al. 17 compared three doses of FAE (120 mg, 360 mg, 720 mg) with placebo, and reported statistically significant reductions in PASI score after 12 weeks, compared with baseline, of 31%, 52% and 71%, respectively (P < 0Á001 compared with placebo for the 360-mg and 720-mg doses). Similarly, Mrowietz et al. 18 reported a median PASI score of 5Á8 after 16 weeks of FAE treatment (n = 105), compared with a median of 14Á2 in the placebo group (n = 70) (P < 0Á001). This represented 67Á8% and 10Á2% reductions, respectively, and an effect size of 7Á4 points (95% CI 5Á40-9Á40). It was not possible to compute the MD in these studies because of unreported mean PASI scores at baseline and follow-up.
In a meta-analysis from two studies 17, 18 including a total of 247 participants, the number of participants who attained PASI 50 was greater with FAEs than with placebo (RR 4Á55, 95% CI 2Á80-7Á40; P < 0Á001; I 2 = 0%; low-quality evidence) (Fig. 3) . The combined PASI 50 was 64% with FAEs, compared with 14% for placebo, representing a number needed to treat to benefit (NNTB) of 2. The other studies comparing FAEs with placebo did not include a PASI score and instead measured the disease severity by estimating the body surface area involved. 19, 20 The dropout rate due to FAE adverse effects was reported clearly in only one study, which was designed for psoriatic arthritis. 20 In this study, two withdrawals occurred in the FAE group (n = 13) compared with no dropouts in the placebo arm (n = 14) (RR 5Á36, 95% CI 0Á28-102Á12; 27 participants; very low-quality evidence). However, this finding is unreliable due to indirectness and very wide CIs. The reasons for dropout in the FAE group were diarrhoea (after 6 weeks) and proteinuria with raised serum creatinine (after 12 weeks). We could not establish the RR of dropouts due to adverse effects alone in the other studies because of unclear 16, 19 or lack 17, 18 of reporting. None of the included studies reported whether the adverse effects that led to treatment discontinuation were serious.
One study 16 reported a higher incidence of nuisance adverse effects (not leading to treatment discontinuation) with FAEs compared with placebo (RR 4Á72, 95% CI 2Á45-9Á08; 99 participants; moderate-quality evidence), affecting 76% of participants given FAEs (n = 49) and 16% of the placebo group (n = 50), representing a number needed to treat to harm of 2. The most common were abdominal pain, diarrhoea and flushing (percentage and RR could not be computed).
A within-group comparison showed a statistically significant decrease of leucocytes with FAEs (P = 0Á016), due to a reduction in lymphocyte count. The eosinophil count was unchanged in the placebo group, and increased in the FAE group from 2% at baseline to 3Á4% at 4 weeks (P < 0Á05), with a further insignificant increase to 4Á7% at week 12.
The maximum increase in eosinophil count was 28% (time point not stated). Another study 19 with a small number of participants in the FAE group (n = 13) reported diarrhoea (100% of participants), flushing (95%) and nausea (46%) as the most common adverse effects. Increased serum creatinine to 238 lmol L À1 and reduced creatinine clearance rate by 51% were reported in one participant (8%) in the FAE group, but this was reversible (unknown whether treatment was stopped prior to improvement of the renal function). Transient increase in liver enzymes (62%), eosinophilia (38%) and lymphopenia (31%) were also reported with FAEs, but it was not clear whether these occurrences were serious or caused treatment discontinuation. In the abstract published by Mrowietz et al., 18 gastrointestinal adverse effects were observed in 58% of participants in the FAE group (n = 105), compared with 23% of those given placebo (n = 70) (RR 2Á54, 95% CI 1Á60-4Á03). Adverse effect severity was described as moderate in 82% of cases (unclear whether any of the remaining 18% dropped out due to severe symptoms). In this abstract, more participants experienced flushing with FAEs in comparison with placebo (42% vs. 9%) (RR 4Á67, 95% CI 2Á09-10Á39). Quality of life was reported in only one abstract, using Skindex-29. 18 The mean score in the FAE group decreased from 54Á7 at baseline to 27Á0 at week 16, in comparison with e Downgraded one level due to indirectness; the study was designed for psoriatic arthritis where all participants also had psoriasis, so may not be directly applicable to those with moderate-tosevere psoriasis.
f Downgraded two levels for imprecision; small sample size and very wide CIs that included the possibility of an effect in either direction (crosses line of no effect). a reduction from 54Á0 to 51Á1 in the placebo arm, a betweengroup difference of À19Á3 points (P < 0Á001).
Comparison of fumaric acid esters with methotrexate
Only one study, involving 60 randomized participants, compared FAEs with methotrexate in an open-label fashion. 21 Thirty participants were assigned to each group, of whom 26 of the FAE group and 25 in the methotrexate group were included in the primary analysis at week 12. The quality of evidence for each outcome is summarized in Table 2 .
The study reported similar efficacy of FAE and methotrexate, with a mean PASI score reduction from 14Á5 at baseline to 6Á7 after 12 weeks in the methotrexate group (n = 25) in comparison with a reduction from 18Á1 to 10Á5 in the FAE group (n = 26). The reported absolute difference after adjustment for baseline values was 1Á4 (95% CI À2Á0 to 4Á7; P = 0Á42). However, when we compared the PASI scores at follow-up (week 12), as recommended by The Cochrane Collaboration, there was a significant difference in favour of methotrexate (MD 3Á80, 95% CI 0Á68-6Á92; very low-quality evidence) (Fig. 4) .
No significant difference was noted between the two groups in the numbers of participants who attained PASI 50 (RR 0Á71, 95% CI 0Á41-1Á22; very low-quality evidence), PASI 75 (RR 0Á80, 95% CI 0Á28-2Á29; very low-quality evidence) and PASI 90 (RR 0Á48, 95% CI 0Á05-4Á98; very low-quality evidence). However, the maximum dose of methotrexate used in this study (15 mg per week) may have been suboptimal, as higher doses can be prescribed in routine clinical practice. Also, the time of assessment at 12 weeks might have been too early to evaluate true efficacy. Although the study reported no significant difference in the number of participants attaining PASI 75 and PASI 90 at week 16, it must be noted that the dose of methotrexate was reduced gradually from week 12, which may have reduced the effect size.
The dropout rate due to adverse effects in both groups was not significantly different (RR 0Á19, 95% CI 0Á02-1Á53; very low-quality evidence) (Fig. 5) . Four participants (16%) in the methotrexate group dropped out because of elevated liver enzymes; another patient dropped out due to recurrent angina unrelated to treatment. Raised liver enzymes were reported to be transient, and normalized 4-8 weeks after treatment discontinuation. Only one participant in the FAE group (4%) discontinued treatment, due to diarrhoea.
Overall, the number of participants experiencing nuisance adverse effects was not significantly different between the two groups (RR 0Á89, 95% CI 0Á77-1Á03; very low-quality evidence). However, more participants experienced flushing in the FAE group (13 vs. two) (RR 6Á50, 95% CI 1Á62-26Á09).
There was no significant difference in reported laboratory findings between the two groups, which may reflect the small study size. Transient increase of liver enzymes (up to double the baseline value) was observed in 11% of participants in the FAE group and 30% of participants given methotrexate (RR 0Á38, 95% CI 0Á11-1Á26). There was transient eosinophilia (maximum measured level 1Á55 9 10 9 cells L À1 ) in five participants in the FAE group, compared with none of those on methotrexate (RR 11Á00, 95% CI 0Á64-189Á65), and transient leucocytopenia (2Á1 9 10 9 cells L À1 ) in one participant in the FAE group, compared with none in the methotrexate group (RR 3Á00, 95% CI 0Á13-70Á53). An equal number of eight participants from each group (30%) showed transient proteinuria (RR 1Á00, 95% CI 0Á44-2Á28).
Discussion
Limited evidence suggests that FAEs are superior to placebo in the treatment of psoriasis, and there is very low-quality evidence to determine the relative efficacy of FAEs compared with methotrexate. Commonly reported adverse effects associated with FAEs include gastrointestinal symptoms (58% of participants in one study), flushing (42%, 48% and 95% in three studies), eosinophilia (19% and 38% in two studies) and reversible proteinuria (30% in one study). However, the evidence provided by this review was limited due to a lack of full reports and inconsistencies of reporting. No long-term studies were identified to comment on the long-term efficacy and safety of FAEs in psoriasis. The small number of included studies and insufficient reporting of outcomes were major limitations to address the objectives of our review. Some studies included participants with various types of psoriasis, but the outcomes reported did not indicate whether the response to FAEs varied between different subgroups. The majority of studies comparing FAEs with placebo did not report the number of participants who Other non-Cochrane systematic reviews have also reported the superiority of FAEs over placebo in the treatment of psoriasis, [24] [25] [26] and similar efficacy to methotrexate. 24, 26 However, GRADEpro assessment of the level of quality of evidence in our review demonstrated that the latter conclusion is unreliable due to the very low quality of evidence. There is a relative paucity of RCTs comparing other conventional oral treatments for psoriasis with placebo. Bansback et al. 27 reported in meta-analyses an RR of PASI 50 response of 4Á74 with methotrexate 15-22Á5 mg weekly (95% CI 3Á52-5Á73), with an NNTB of 2; and 4Á06 with ciclosporin 3 mg kg À1 per day (95% CI 2Á54-5Á73), with an NNTB of 2. These are comparable with our findings of FAE efficacy with a PASI 50 RR of 4Á55 compared with placebo (95% CI 2Á80-7Á40) and an NNTB of 2. However, the dropout rates and risk of adverse effects were not reported by Bansback et al. Three RCTs from the 1980s [28] [29] [30] demonstrated that acitretin 50-75 mg daily was significantly better than placebo and a lower acitretin dose (10-25 mg daily) in treating psoriasis, but no PASI scores were reported and the dropout rate due to adverse effects was unclear. A Cochrane systematic review is currently underway to examine all systemic pharmacological interventions for psoriasis. 31 Most of the studies included in our review were not fully reported and were performed before the requirement of trial registration. As a result we downgraded the evidence quality to low or very low. The findings in our review reinforce the conclusion of the European S3 guidelines that 'although the use of fumarates for psoriasis has been evaluated in clinical trials, only a small number of these have followed the criteria of evidence-based medicine'. 22 Our review also highlights the inadequate reporting of adverse effects, which should be based on the Consolidated Standards of Reporting Trials (www.consort-statement.org). Application of these standards and consistency in reported outcomes based on the Core Outcome Measures in Effectiveness Trials initiative are necessary to enhance the quality and robustness of evidence in future FAE trials. There remains a need to establish the long-term safety of FAEs, an evidence gap that is being addressed by the British Association of Dermatologists' Biologic Interventions Register 32 and other psoriasis databases.
